Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation

Blood

Volumn 126, Issue 8, 2015, Pages 1027-1032

  Pascal, Laurent ^a,c   Tucunduva, Luciana ^d   Ruggeri, Annalisa ^d,e   Blaise, Didier ^f   Ceballos, Patrice ^g   Chevallier, Patrice ^h   Cornelissen, Jan ⁱ   Maillard, Natacha ^j   Tabrizi, Reza ^k   Petersen, Eefke ^l   Linkesch, Werner ^m   Sengeloev, Henrik ⁿ   Kenzey, Chantal ^d   Pagliuca, Antonio ^o   Holler, Ernst ^p   Einsele, Hermann ^q   Gluckman, Eliane ^d,r   Rocha, Vanderson ^d,s   Yakoub Agha, Ibrahim ^b,c,t   Eurocord, ^u   European Society for Blood and Marrow Transplantation, ^u   more..

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE LILLE   (France)

^d EUROCORD   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g LAPEYRONIE HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j POITIERS UNIVERSITY HOSPITAL   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁿ Rigshospitalet   (Denmark)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p UNIVERSITY OF REGENSBURG   (Germany)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r Monacord   (Monaco)

^s CHURCHILL HOSPITAL   (United Kingdom)

^t LILLE UNIVERSITY HOSPITAL   (France)

^u NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; RELAPSE; UNRELATED CORD BLOOD TRANSPLANTATION; WHOLE BODY RADIATION; ADOLESCENT; ALLOGRAFT; ANALOGS AND DERIVATIVES; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROCEDURES; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTILYMPHOCYTE SERUM; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84940036179     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599241     Document Type: Article

References (28)

1. Rocha V, Labopin M, Sanz G, et al Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276-2285.
2. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265-2275.
3. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115(9):1843-1849.
4. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178.
5. Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol.2009;27(2):256-263.
6. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335(3):157-166.
7. Pascal L, Mohty M, Ruggeri A, et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant. 2015;50(1):45-50.
8. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102(5):1915-1919.
9. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13(1):82-89.
10. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989;86(10):3828-3832.
11. Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543-4551.
12. Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5:68.
13. Moretta A, Maccario R, Fagioli F, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 2001;29(3):371-379.
14. Niehues T, Rocha V, Filipovich AH, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children - a Eurocord analysis. Br J Haematol. 2001;114(1):42-48.
15. Locatelli F, Maccario R, Comoli P, et al. Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children. Bone Marrow Transplant. 1996;18(6):1095-1101.
16. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-1394.
17. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947.
18. Mohty M, Gaugler B. Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. Best Pract Res Clin Haematol. 2010;23(2):275-282.
19. Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between antithymocyte globulin exposure and CD41 immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194-e203.
20. Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):959-970.
21. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110(8):3064-3070.
22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc. 1999;94(446):496-509.
26. Sanz J, Boluda JCH, Martín C, et al Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH). Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant. 2012;47(10):1287-1293.
27. Lindemans CA, Chiesa R, Amrolia PJ, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood. 2014;123(1):126-132.
28. Mohty M, Labopin M, Balère ML, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia. 2010;24(11):1867-1874.